Patent Application Serial No.: 10/598,841

Attorney Docket No.: PC32216

Page 3 of 13

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A compound of the formula

$$R_2 \xrightarrow{R_1} N \xrightarrow{N} NH$$

$$X_2 \\ R_3$$

or a pharmaceutically acceptable salt thereof, wherein:

X₁ is CH₂, NH, or O;

X₂ is absent, or is

$$(CH_2)_x$$
, NH, O, or $e^{\frac{1}{2}}$, $e^{\frac{1}{2}}$, wherein "...." are points of attachment, or

is a tether 2, 3 or 4 atoms in length, selected from

wherein "ww" are points of attachment and x' is an integer from 1 to 3;

Y is N, C-H, C-F, or C-OMe;

R₁ is H or halo;

R₂ is (C₃-C₆)cycloalkyl,

(CH₂)_x-aryl,

 $(CH_2)_x$ heterocyclo-heterocyclyl, or

(CH₂)_x-heteroaryl,

wherein x is 0, 1, or 2;

R₃ is H,

```
(C<sub>1</sub>-C<sub>6</sub>)alkyl,
(C<sub>3</sub>-C<sub>8</sub>)cycloalkyl,
aryl,
heterociclo-heterocyclyl,
heteroaryl,
C(O)NR<sub>a</sub>R<sub>b</sub>,
C(O)R<sub>a</sub>,
CO<sub>2</sub>R<sub>a</sub>,
C(O)C(O)NR_aR_b,
NO<sub>2</sub>,
SO<sub>2</sub>R<sub>a</sub>,
SO<sub>2</sub>NR<sub>a</sub>R<sub>b</sub>,
C(R_c)=NOR_a
C(R_c)=NR_a
                , wherein "	" indicates the point of attachment,
                      , wherein " indicates the point of attachment,
and wherein
                         (C1-C6)alkyl,
                         (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
                         (CH<sub>2</sub>)<sub>y</sub>-aryl,
                         (CH<sub>2</sub>)<sub>y</sub>-heterocycle heterocyclyl, or
                         (CH<sub>2</sub>)<sub>v</sub>-heteroaryl,
            wherein y is 0, 1, or 2;
            R<sub>b</sub> is H,
                         (C1-C6)alkyl,
                         (C3-C6)cycloalkyl,
                         aryl,
                         heterocyclo heterocyclyl, or
                         heteroaryl;
```

 R_c is H,

Patent Application Serial No.: 10/598,841 Attorney Docket No.: PC32216

Page 5 of 13

```
(C<sub>1</sub>-C<sub>6</sub>)alkyl,
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
aryl,
heterocycle heterocyclyl, or
heteroaryl; and
```

 R_4 is (C1-C6)alkyl, (C1-C6alkyl)-O-(C1-C6alkyl), cyclopropyl, CH_2 -cyclopropyl, or cyclobutyl.

2. (Cancelled).

and,

- 3. (Currently Amended) A compound according to claim 1 in which Y is C-H or a pharmaceutically acceptable salt thereof.
- (Currently Amended) A compound according to anyone of claims 1-3 in which X₁ is NH,
 X₂ is absent, or is (CH₂)_x, NH, or O;

 R_4 is (C₁-C₆)alkyl, cyclopropyl, CH₂-cyclopropyl or cyclobutyl, <u>or a pharmaceutically acceptable salt thereof.</u>

5. (Currently Amended) A compound according to anyone of claims 1-4 in which R₂ is heteroaryl or a pharmaceutically acceptable salt thereof.

Patent Application Serial No.: 10/598,841 Attorney Docket No.: PC32216

Page 6 of 13

6. (Currently Amended) A compound according to anyone of claims 1-5 in which R₂ is heteroaryl and is selected from the group consisting of pyridine, and pyrimidine, either of which may be optionally substituted, or a pharmaceutically acceptable salt thereof.

- 7. (Currently Amended) A compound according to anyone of claims 1-6 in which X2 is absent and R₃ is hydrogen, heteroaryl, C(O)NR_aR_b, C(O)R_a, or CO₂R_a, or a pharmaceutically acceptable salt thereof.
- 8. (Currently Amended) A compound according to anyone of claims 1-7 in which R₄ is ethyl or cyclobutyl, or a pharmaceutically acceptable salt thereof.
- 9. (Currently Amended) A compound selected from the group consisting of:

(7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-carbamic acid ethyl ester;

1-ethyl-3-(7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea;

[7-(2-dimethylamino-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-carbamic acid ethyl ester;

1-[7-(2-dimethylamino-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;

[7-(6-methoxy-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-carbamic acid ethyl ester;

1-ethyl-3-[7-(6-methoxy-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;

1-ethyl-3-[7-(2-methoxy-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl)-urea;

(7 pyridin 3 yl-imidazo[1,2 c]pyrimidin 2 yl) carbamic acid ethyl esters;

1-ethyl-3-{7-[6-(2-morpholin-4-yl-ethoxy)-pyridin-3-yl]-imidazo[1,2-a]pyridin-2-yl}-urea;

1-ethyl-3-(5-hydroxymethyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea;

1-ethyl-3-(5-formyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea;

2-(3-ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridine-5-carboxylic acid methyl ester;

1-ethyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea;

1-[7-(3,5-dimethyl-isoxazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;

1-[7-(1-benzyl-1H-pyrazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;

1-ethyl-3-{7-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-imidazo[1,2-a]pyridin-2-yl}-urea;

1-ethyl-3-[7-(1-methyl-1H-pyrazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;

1-[7-(2,4-dimethoxy-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;

4-[2-(3-ethyl-ureido)-imidazo[1,2-a]pyridin-7-yl]-3,5-dimethyl-pyrazole-1-carboxylic acid tertbutyl ester;

1-ethyl-3-[7-(1H-pyrazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;

1-(3-chloro-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-3-ethyl-urea;

1-[3-chloro-7-(2-dimethylamino-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;

2-(3-ethyl-ureido)-imidazo[1,2-a]pyridine-7-carboxylic acid methyl ester;

2-(3-ethyl-ureido)-imidazo[1,2-a]pyridine-7-carboxylic acid amide;

and the second second

1-ethyl-3-[7-(5-methyl-2H-[1,2,4]triazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;

Attorney Docket No.: PC32216

Page 7 of 13

```
1-[7-(1,5-dimethyl-1H-[1,2,4]triazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea; and
```

- 1-[7-(2,5-dimethyl-2H-[1,2,4]triazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- 1-ethyl-3-[7-(5-methyl-[1,2,4]oxadiazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-ethyl-3-[5-(1-methyl-1H-pyrazol-4-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- 2-(3-ethyl-ureido)-imidazo[1,2-a]pyridine-7-carboxylic acid;
- 1-[7-(3,5-dimethyl-1H-pyrazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- 1-ethyl-3-[7-(piperidine-1-carbonyl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-cyclopropyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 1-cyclopropylmethyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 1-propyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 1-isopropyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 1-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-3-(2,2,2-trìfluoro-ethyl)-urea;
- 1-(2-methoxy-ethyl)-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 1-cyclobutyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 1-[7-(6-amino-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- N-(7-acetylimidazo[1,2-a]pyridin-2-yl)-N-ethylurea;
- 1-ethyl-3-[7-(5-methyl-[1,3,4]oxadiazol-2-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- {4-[2-(3-ethyl-ureido)-imidazo[1,2-a]pyridin-7-yl]-pyridin-2-yl}-carbamic acid tert-butyl ester;
- 1-ethyl-3-[7-(2H-pyrazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-ethyl-3-(7-[1,2,3]thiadiazol-4-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 1-ethyl-3-[7-(5-isopropyl-[1,2,4]oxadiazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-ethyl-3-[7-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- {4-[2-(3-ethyl-ureido)-imidazo[1,2-a]pyridin-7-yl]-pyridin-2-yl}-carbamic acid tert-butyl ester;

compound with

- 1-[7-(2-amino-pyridin-4-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- 1-ethyl-3-[7-(morpholine morpholinyl-4-carbonyl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-ethyl-3-[7-(2-methoxy-pyridin-4-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-ethyl-3-[5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-ethyl-3-[7-(6-fluoro-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-ethyl-3-[7-(1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-ethyl-3-[7-(6-methyl-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-ethyl-3-[7-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 7-(2-dimethylamino-pyrimidin-5-yl)-2-(3-ethyl-ureido)-imidazo[1,2-a]pyridine-5-carboxylic acid ethylamide, and
- 1-[7-(2-dimethylamino-pyrimidin-5-yl)-5-pyrimidin-2-yl-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea<u>, or</u> a pharmaceutically acceptable salt thereof.
- 10. (Currently Amended) A compound selected from the group consisting of:

Patent Application Serial No.: 10/598,841

Attorney Docket No.: PC32216

Page 8 of 13

- 1-ethyl-3-(7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 1-ethyl-3-[7-(6-methoxy-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-ethyl-3-[7-(2-methoxy-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-ethyl-3-(5-hydroxymethyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 1-ethyl-3-(5-formyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 2-(3-ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridine-5-carboxylic acid methyl ester;
- 1-ethyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 1-ethyl-3-[5-(1-methyl-1H-pyrazol-4-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-propyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 1-cyclobutyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 1-[7-(6-amino-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- 1-ethyl-3-[7-(2H-pyrazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-ethyl-3-(7-[1,2,3]thiadiazol-4-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 1-ethyl-3-[7-(2-methoxy-pyridin-4-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-ethyl-3-[5-(3-methyl-[1,2,4]oxadiazol-5-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- 1-ethyl-3-[7-(6-fluoro-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 7-(2-dimethylamino-pyrimidin-5-yl)-2-(3-ethyl-ureido)-imidazo[1,2-a]pyridine-5-carboxylic acid ethylamide, and
- 1-[7-(2-dimethylamino-pyrimidin-5-yl)-5-pyrimidin-2-yl-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea<u>, or a pharmaceutically acceptable salt thereof.</u>
- 11. (Currently Amended) A pharmaceutical formulation comprising a compound according to anyone of claims 1–10 admixed with a pharmaceutically acceptable diluent, carrier, or excipient.
- 12. (Cancelled).
- 13. (Cancelled).